Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

David Filmore

Executive Editor

Rochester, NY
David Filmore has been covering the health care sector as a writer and editor for 16 years. He specializes in devices and diagnostics, particularly focusing on the regulatory and reimbursement dynamics that impact a company’s ability to succeed in the marketplace. Originally trained as a scientist, Dave enjoys dissecting technical topics to reach a core understanding. As a writer and editor, he relishes communicating that understanding, important context and key takeaways for practical use by the reader. Dave has led operations or served on the staff of “The Gray Sheet” for more than a decade, and now oversees Regulatory and Policy content for the new Medtech Insight. Previously, he was an editor with the American Chemical Society, producing content for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the pharma industry, and has a degree in chemistry. Dave lives with his wife and two kids in Rochester, NY.
Advertisement
Set Alert for Articles By David Filmore

Latest From David Filmore

Inside The Spinal Cord: InVivo Therapeutics Looks To Reverse Injury, Leverage Regulatory Reforms

InVivo Therapeutics is looking to build on a breakthrough in understanding the pathophysiology of spinal cord injury to bring the first device to market for partially reversing the debilitating condition. The firm is dealing with a cautious FDA in its pivotal-trial development, but also looking to leverage a new US policy for humanitarian-use devices to expedite its path to market expansion.

Neurology Innovation

FDA 510(k)-Exempts 72 Devices, Mostly Diagnostics

The US agency has exempted 72 different class I device types from the 510(k) requirement, effective April 13, using a procedure laid out by the 21st Century Cures Act. A majority of the products are in vitro diagnostics and reagents, but there also devices such as patient beds, restraints and first-aid kits.

Regulation FDA

Conference Collaboration Sign Of Growing AdvaMed, MDMA Partnership

While the two US-based medical device lobby groups, AdvaMed and MDMA, may have butted heads in the past, they are showing an increasing level of cooperation, most recently with plans to partner on the upcoming Medtech Conference in San Jose.

Medical Device United States

US Approvals Analysis: Biotronik Making Its Interventional Mark

The German-headquartered firm is making a play to enter the US vascular intervention market, with two stents approved by FDA under original PMAs in the first quarter of 2017. Cardiovascular devices, in general, have gained the most novel-device approvals so far this year, followed by IVDs. Check out more from a Q1 look at US FDA approvals and clearances monitored by Medtech Insight's Approvals Tracker.

Cardiology Cancer

Former Siemens CMO Tapped To Run US Health IT Policy

Donald Rucker, who spent 13 years as chief medical officer of Siemens Healthcare, has been tapped as the US National Coordinator of Health IT, according to a government directory listing.

Policy Medical Device

Device-Tax Repeal Opportunity Slips Away As GOP Pulls Health Bill From Consideration

The House Republican conference decision to pull the American Health Care Act from consideration means repeal of the medical device tax has died, at least in the short term. After hours of debate on the floor, and failing to gather enough votes to pass the bill, House Speaker Paul Ryan and President Trump called a halt to the Affordable Care Act repeal effort, saying they will now focus on other objectives, such as tax reform.

Policy Legislation
See All
Advertisement
UsernamePublicRestriction

Register